Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation

Author(s): Ying Zhang, Kongkai Zhu, Juan Zhang, Jin-He Zhang, Zhiling Song, Xinlei Zhang*, Shan-Kui Liu and Cheng-Shi Jiang*

Volume 29, Issue 6, 2023

Published on: 06 March, 2023

Page: [474 - 479] Pages: 6

DOI: 10.2174/1381612829666230215105046

Price: $65

Abstract

Background: PRMT5 is a major enzyme responsible for the post-translational symmetric demethylation of protein arginine residues, which has been validated as an effective therapeutic target for cancer. Thus, many nucleoside-based PRMT5 inhibitors have been reported in the past year.

Objective: To discover a novel series of non-nucleoside PRMT5 inhibitors through a molecular docking-based virtual screening approach.

Methods: Our in-house compound library was virtually screened using the Glide program, identifying a new PRMT5 inhibitor 1. Based on the structural similarity of hit 1, a series of structure-oriented derivatives, including 3a-3e, 7a-7g, and 12a-12f, were synthesized and selected for the inhibitory activity evaluation against PRMT5, as well as cytotoxicity against MV4-11 cell.

Results: The analogs 7a-7e with benzimidazole core exhibited potent PRMT5 inhibitory activities, with 7e displaying the most potent activity with an IC50 of 6.81 ± 0.12 μM. In the anti-proliferative assay, compound 7e showed a strong inhibitory effect on MV4-11 cell growth. Finally, the binding mode of 7e with PRMT5 was predicted to provide insights for further structural optimization.

Conclusion: The newly discovered PRMT5 inhibitors have potential antitumor activity against MV4-11 cells. This work highlighted this series of 3-(1H-benzo[d]imidazol-2-yl)aniline derivatives as novel anti-cancer lead compounds targeting PRMT5, which were worthy of further investigation.

« Previous
[1]
Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes Dis 2019; 6(3): 247-57.
[http://dx.doi.org/10.1016/j.gendis.2019.06.002] [PMID: 32042864]
[2]
Tewary SK, Zheng YG, Ho MC. Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic level. Cell Mol Life Sci 2019; 76(15): 2917-32.
[http://dx.doi.org/10.1007/s00018-019-03145-x] [PMID: 31123777]
[3]
Sapir T, Shifteh D, Pahmer M, Goel S, Maitra R. Protein arginine methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K pathways: A case for PRMT5 inhibition and combination therapies in cancer. Mol Cancer Res 2021; 19(3): 388-94.
[http://dx.doi.org/10.1158/1541-7786.MCR-20-0745] [PMID: 33288733]
[4]
Lee MKC, Grimmond SM, McArthur GA, Sheppard KE. PRMT5: An emerging target for pancreatic adenocarcinoma. Cancers 2021; 13(20): 5136.
[http://dx.doi.org/10.3390/cancers13205136] [PMID: 34680285]
[5]
Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond. Cell Mol Life Sci 2015; 72(11): 2041-59.
[http://dx.doi.org/10.1007/s00018-015-1847-9] [PMID: 25662273]
[6]
Chen Y, Shao X, Zhao X, et al. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms. Biomed Pharmacother 2021; 144: 112252.
[http://dx.doi.org/10.1016/j.biopha.2021.112252] [PMID: 34619493]
[7]
Liang Z, Wen C, Jiang H, Ma S, Liu X. Protein arginine methyltransferase 5 functions via interacting proteins. Front Cell Dev Biol 2021; 9: 725301.
[http://dx.doi.org/10.3389/fcell.2021.725301] [PMID: 34513846]
[8]
Kim H, Kim H, Feng Y, et al. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med 2020; 12(551): eaaz5683.
[http://dx.doi.org/10.1126/scitranslmed.aaz5683] [PMID: 32641491]
[9]
Litzler LC, Zahn A, Meli AP, et al. PRMT5 is essential for B cell development and germinal center dynamics. Nat Commun 2019; 10(1): 22.
[http://dx.doi.org/10.1038/s41467-018-07884-6] [PMID: 30604754]
[10]
Banasavadi-Siddegowda YK, Welker AM, An M, et al. PRMT5 as a druggable target for glioblastoma therapy. Neurooncol 2018; 20(6): 753-63.
[http://dx.doi.org/10.1093/neuonc/nox206] [PMID: 29106602]
[11]
Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: A review. J Immuno Precis Oncol 2022; 5(3): 58-67.
[http://dx.doi.org/10.36401/JIPO-22-1] [PMID: 36034581]
[12]
Villar MV, Spreafico A, Moreno V, et al. 537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers. Ann Oncol 2020; 31: S470.
[http://dx.doi.org/10.1016/j.annonc.2020.08.651]
[13]
Kaniskan HÜ, Jin J. Recent progress in developing selective inhibitors of protein methyltransferases. Curr Opin Chem Biol 2017; 39: 100-8.
[http://dx.doi.org/10.1016/j.cbpa.2017.06.013] [PMID: 28662389]
[14]
Lin H, Luengo JI. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors. Bioorg Med Chem Lett 2019; 29(11): 1264-9.
[http://dx.doi.org/10.1016/j.bmcl.2019.03.042] [PMID: 30956011]
[15]
Wang Y, Hu W, Yuan Y. Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery. J Med Chem 2018; 61(21): 9429-41.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00598] [PMID: 29870258]
[16]
Zhu K, Shao J, Tao H, et al. Rational design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. J Comput Aided Mol Des 2019; 33(8): 775-85.
[http://dx.doi.org/10.1007/s10822-019-00214-y] [PMID: 31312965]
[17]
Mao R, Shao J, Zhu K, et al. Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization. J Med Chem 2017; 60(14): 6289-304.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00587] [PMID: 28650658]
[18]
Zhu K, Song JL, Tao HR, Cheng ZQ, Jiang CS, Zhang H. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors. Bioorg Med Chem Lett 2018; 28(23-24): 3693-9.
[http://dx.doi.org/10.1016/j.bmcl.2018.10.026] [PMID: 30366617]
[19]
Zhu K, Tao H, Song JL, et al. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations. Bioorg Chem 2018; 81: 289-98.
[http://dx.doi.org/10.1016/j.bioorg.2018.08.021] [PMID: 30172110]
[20]
Tao H, Yan X, Zhu K, Zhang H. Discovery of novel PRMT5 inhibitors by virtual screening and biological evaluations. Chem Pharm Bull 2019; 67(4): 382-8.
[http://dx.doi.org/10.1248/cpb.c18-00980] [PMID: 30930442]
[21]
Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47(7): 1739-49.
[http://dx.doi.org/10.1021/jm0306430] [PMID: 15027865]
[22]
Li Y, Zhang JH, Xie HX, et al. Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation. Bioorg Chem 2021; 117: 105423.
[http://dx.doi.org/10.1016/j.bioorg.2021.105423] [PMID: 34717239]
[23]
Zhang J, Cheng ZQ, Song JL, et al. Synthesis and biological evaluation of 2-(3-aminophenyl)-benzothiazoles as antiproliferative and apoptosis-inducing agents. Monatsh Chem 2018; 149(11): 2093-102.
[http://dx.doi.org/10.1007/s00706-018-2274-z]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy